Amrut Medhekar to exit Akums Drugs and Pharma as CEO-CDMO Business

New Delhi:  Akums Drugs and Pharma has announced the resignation of Amrut Medhekar, CEO- CDMO Business of the Company effective July 15 to pursue new opportunities and challenges.

“In terms of Regulation 30 and 33 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company in its meeting held on 26th May, 2025 has accepted resignation of Mr. Amrut Medhekar, CEO (CDMO) of the Company w.e.f 15.07.2025,” AKums stated in a BSE filing.

He is a seasoned business leader with 28+ years of versatile experience spanning General Management, Sales, Marketing, and Functional Leadership in the pharmaceutical industry.

Before joining Akums, Medhekar held the position of President, India Business at Wockhardt. He also spent over 13 years at Zydus Group, where he successfully led Acute as well as Chronic therapy business clusters– Antibiotics, Gastroenterology, Cardiology & Diabetes, Orthopedics, Rheumatology, Ophthalmology, Nutrition etc. He also led critical functions as – Commercial Excellence/ Strategy, SFE, Portfolio & Business Development, Marketing excellence & Digital, Business Insights & Key account/ Institution business, Nepal Business.

Medhekar’s earlier roles included leadership positions at Ranbaxy, Torrent Pharmaceuticals, LifeMedicare Biotech, Novartis, and even outside the pharma space at JK Tyre & Industries Ltd.

Read also: Akum Drugs Gets CDSCO Panel Nod To Conduct Post Marketing Surveillance study of Linezolid Sustained Release Tablets

Akums Drugs & Pharmaceuticals Ltd. is a contract-manufacturing pharmaceutical company of India. The organization deals in the manufacturing and export of formulations in a wide spectrum of dosage forms & therapeutic segments. The company is currently supplying to almost all Indian and multinational pharmaceutical companies across the globe. The 10 state-of-the-art facilities are dedicated to oral solid dosage forms (with separate units for beta lactum and non-beta lactum formulations), Oral liquid dosage forms, Sterile dosage forms (Injectable, eye, ear & nasal), hormonal (oral and injectable), Ointments & cosmetics, Ayurvedic, food supplements & nutraceuticals and animal health care.

The organization is certified with WHO-GMP, ISO 9001 : 2008, ISO 14001:2004 certificates and various international accreditations, like; ANVISA, Brazil, NAFDAC, Nigeria, FDB, Ghana, PMPB, Malawi amongst others.

Related Posts

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India